Abstract
Adenosine is a ubiquitous homeostatic substance which exerts its action by triggering four different cell membrane G protein-coupled receptors, classified as A1, A2A, A2B, and A3. As they are widely distributed and deeply involved in several physiological functions, as well as pathological disorders, these receptors represent an excellent drug target, and the development of specific ligands has been tested as a promising therapeutic concept. Among the obtainable ligands, allosteric modulators offer higher advantages with respect to classical orthosteric compounds, as they make it possible to achieve greater selectivity and better modulatory control at disease mediating receptors. Actually, when synergizing with adenosine bound to the primary binding site, these compounds may modify receptor functions through interaction with an additional binding site. As a consequence, their actions depend directly on the release of the endogenous agonist. A number of compounds have been developed as effective allosteric modulators. Most of them target adenosine A1 and A3 receptor subtypes whereas, to date, little or no research has been made to improve the field of A2A or A2B ligands. This review updates literature on the allosteric modulators that has appeared in the last few years, focusing its attention on medicinal chemistry, in terms of chemical structure and structure-activity relationships. This will provide new perspectives on existing data, and an exciting starting point for the development of novel and more effective modulators.
Keywords: Adenosine, A1, A2A, A2B, A3 adenosine receptors, allosteric modulators
Current Topics in Medicinal Chemistry
Title: Allosteric Modulators for Adenosine Receptors: An Alternative to the Orthosteric Ligands
Volume: 10 Issue: 10
Author(s): C. La Motta, S. Sartini, M. Morelli, S. Taliani and F. Da Settimo
Affiliation:
Keywords: Adenosine, A1, A2A, A2B, A3 adenosine receptors, allosteric modulators
Abstract: Adenosine is a ubiquitous homeostatic substance which exerts its action by triggering four different cell membrane G protein-coupled receptors, classified as A1, A2A, A2B, and A3. As they are widely distributed and deeply involved in several physiological functions, as well as pathological disorders, these receptors represent an excellent drug target, and the development of specific ligands has been tested as a promising therapeutic concept. Among the obtainable ligands, allosteric modulators offer higher advantages with respect to classical orthosteric compounds, as they make it possible to achieve greater selectivity and better modulatory control at disease mediating receptors. Actually, when synergizing with adenosine bound to the primary binding site, these compounds may modify receptor functions through interaction with an additional binding site. As a consequence, their actions depend directly on the release of the endogenous agonist. A number of compounds have been developed as effective allosteric modulators. Most of them target adenosine A1 and A3 receptor subtypes whereas, to date, little or no research has been made to improve the field of A2A or A2B ligands. This review updates literature on the allosteric modulators that has appeared in the last few years, focusing its attention on medicinal chemistry, in terms of chemical structure and structure-activity relationships. This will provide new perspectives on existing data, and an exciting starting point for the development of novel and more effective modulators.
Export Options
About this article
Cite this article as:
La Motta C., Sartini S., Morelli M., Taliani S. and Da Settimo F., Allosteric Modulators for Adenosine Receptors: An Alternative to the Orthosteric Ligands, Current Topics in Medicinal Chemistry 2010; 10 (10) . https://dx.doi.org/10.2174/156802610791293136
DOI https://dx.doi.org/10.2174/156802610791293136 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Treatment of Diabetic Foot Ulcers
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) An Insight into Anticancer Bioactives from <i>Punica granatum</i> (Pomegranate)
Anti-Cancer Agents in Medicinal Chemistry Climate Changes and Human Health: A Review of the Effect of Environmental Stressors on Cardiovascular Diseases Across Epidemiology and Biological Mechanisms
Current Pharmaceutical Design Advances in Matrix Metalloproteinase Inhibitors Based on Pyrrolidine Scaffold
Current Medicinal Chemistry General Anesthetics in Brain Injury: Friends or Foes?
Current Pharmaceutical Design Targeting JAK/STAT Signaling Pathway in Inflammatory Diseases
Current Signal Transduction Therapy Indispensable Roles of Plastids in Arabidopsis thaliana Embryogenesis
Current Genomics Chemical Connexin Impairment in the Developing Gonad Associated with Offspring Infertility
Current Medicinal Chemistry Green Tea from the Far East to the Drug Store: Focus on the Beneficial Cardiovascular Effects
Current Pharmaceutical Design Isolation, Structural Determination, and Evaluation of the Biological Activity of 20(S)-25-methoxyl-dammarane-3β, 12β, 20-triol [20(S)-25-OCH3-PPD], a Novel Natural Product from Panax notoginseng
Medicinal Chemistry Atypical Takotsubo Cardiomyopathy with Hypokinetic Left Mid-ventricle and Apical Wall Sparing: A Case Report and Literature Review
Current Cardiology Reviews A Focus on Microfluidics and Nanotechnology Approaches for the Ultra Sensitive Detection of MicroRNA
MicroRNA Anticancer Activities and Mechanisms of Bisdioxopiperazine Compounds Probimane and MST-16
Anti-Cancer Agents in Medicinal Chemistry Generation of Mesenchymal Stem Cells by Blood Cell Reprogramming
Current Stem Cell Research & Therapy Pharmacological Therapy in Children with Atrioventricular Reentry: Which Drug?
Current Pharmaceutical Design Pharmacological Characterisation of Spider Antimicrobial Peptides
Protein & Peptide Letters Threes Company: Regulation of Cell Fate by Statins
Current Drug Targets - Cardiovascular & Hematological Disorders Notch Inhibitors as a New Tool in the War on Cancer: A Pathway to Watch
Current Pharmaceutical Biotechnology The Effect of Adult and Pediatric Cardiopulmonary Bypass on Pharmacokinetic and Pharmacodynamic Parameters
Current Clinical Pharmacology Medicinal Plants with Multiple Effects on Cardiovascular Diseases: A Systematic Review
Current Pharmaceutical Design